AT Impf 100 Beteiligungs GmbH

Overview
AT Impf 100 Beteiligungs GmbH — commonly the "AT Impf holding" — is the Strüngmann family-office investment holding vehicle used to hold the founding stake in BioNTech SE. It deployed the approximately 150 million euro seed capital that Andreas Strüngmann and Thomas Strüngmann provided to BioNTech in 2008 and has remained the single largest external shareholder in the company through the 2019 NASDAQ IPO and the 2023 partial secondary sales.
What it is
AT Impf 100 Beteiligungs GmbH is a special-purpose investment holding vehicle (Schema.org type: Organization) rather than a philanthropic foundation. It exists to hold one primary position — BioNTech SE — for joint owners Andreas Strüngmann and Thomas Strüngmann. The name is telling: "Impf" (short for Impfstoff, German for vaccine) signals a dedicated vaccine-anchor mandate. The legal form is a German GmbH (Beteiligungsgesellschaft), managed from Munich.
Structural role in the Strüngmann family office
AT Impf sits inside a layered Strüngmann family-office structure: Santo Holding GmbH (Zug) at the top, Athos Service GmbH and Athos KG in Munich as the operational management arm, and purpose-built vehicles at the portfolio-company level — of which AT Impf (for BioNTech) and ATS Beteiligungsverwaltung GmbH (for Ganymed Pharmaceuticals) are the two named public examples. This per-company pattern lets a single family office run a concentrated, patient-capital portfolio without contaminating governance across positions.
Notable holdings and investments
BioNTech SE is AT Impf's primary and defining holding. The vehicle deployed the approximately 150 million euro 2008 seed to the newly founded BioNTech (Mainz; co-founders Uğur Şahin, Özlem Türeci and Christoph Huber), participated in the 325 million US dollar Series B in 2018, and held approximately 50 percent at the October 2019 NASDAQ IPO — valued at approximately 1.7 billion US dollars at listing. At BioNTech's August 2021 market-capitalisation peak above 100 billion US dollars the AT Impf-mediated stake was valued at more than 50 billion US dollars — one of the largest single-position venture returns on record. AT Impf retained an approximately 43.5 percent joint Strüngmann stake through and after the November 2023 partial secondary sales.
Startuprad.io relevance
AT Impf 100 Beteiligungs GmbH is a pillar entity in the Startuprad.io knowledge graph as the canonical DACH mRNA anchor-capital vehicle. It is the numerical spine of the Strüngmann–Şahin–Hopp anchor triangle, sitting alongside Dietmar Hopp's dievini as one of the two family-office anchors behind the European mRNA industry in the 2020 to 2021 pandemic window.
Public source context
Public references include the https://en.wikipedia.org/wiki/BioNTech and the https://www.cbinsights.com/investor/at-impf . Precise Handelsregister details, the exact 2008 seed figure within the 136.5 to 180 million euro source range, and the current sibling-SPV inventory are open editorial questions.

About this record. This is the public Level 1 layer of Startuprad.io's entity intelligence architecture. Startuprad.io's deeper entity intelligence may include extended profiles, verified relationships, source trails, historical development, monitoring, news signals, custom entity sets, and analytical relationship mapping. These deeper layers are available through Startuprad.io's research, intelligence, and enterprise services.

Need deeper entity intelligence? Startuprad.io provides extended profiles, monitored entity sets, relationship analysis, source-backed research, and custom intelligence services for companies, investors, and institutions. → https://www.startuprad.io/become-a-partner

About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.

Canonical record: https://www.startuprad.io/entities/at-impf-holding